Skip to main content

Table 2 Associations of the single-nucleotide polymorphisms rs2231142 in ABCG2 with comorbidities of the gout patients

From: ABCG2 gene polymorphism rs2231142 is associated with gout comorbidities but not allopurinol response in primary gout patients of a Chinese Han male population

Comorbidities (with/without)

 

(1) GG

(2) TG

(3) TT

(1)vs.(2)vs.(3) F/x2, P value

(1)vs.(2) F/x2, P value

(1)vs.(2)

OR

(95% CI)

(1)vs.(3) F/x2, P value

(1)vs.(3)

OR

(95%CI)

(2)vs.(3) F/x2, P value

(2)vs.(3)

OR

(95%CI)

Hypertention

W/Oa

198/110

340/226

175/120

1.952,0.377

1.19

1.08

0.91

(n = 713)

%b

64.3

60.1

59.3

  

(0.91–1.44)

 

(0.79–1.48)

 

(0.69–1.20)

Diabetes

W/O

48/270

109/471

54/241

2.033,0.362

0.95

1.23

1.29

(n = 211)

%b

15.1

18.8

18.3

  

(0.60–1.51)

 

(0.70–2.15)

 

(0.79–2.12)

Hyperlipidaemia

W/O

215/106

387/202

206/95

0.684,0.711

1.17

1.39

1.2

(n = 808)

%b

67.0

65.7

68.4

  

(0.87–1.59)

 

(0.91–1.99)

 

(0.86–1.63)

Obesity

W/O

234/63

411/140

209/73

2.276,0.320

1.44

1.75

1.21

(n = 854)

%b

78.8

74.6

74.1

  

(1.09–1.90)

 

(1.26–2.43)

 

(0.90–1.64)

Tophi

W/O

62/214

116/414

68/202

1.137,0.566

1.02

0.84

0.83

(n = 246)

%b

22.5

21.9

25.2

  

(0.71–1.44)

 

(0.57–1.25)

 

(0.59–1.17)

Nephrolithiasis

W/O

62/231

109/450

39/267

8.495,0.014

0.331,0.565

0.78

7.561,0.006

0.54

6.361,0.012

0.60

(n = 210)

%b

21.2

19.5

12.7

  

(0.55–1.12)

 

(0.35–0.84)

 

(0.41–0.90)

CKD

W/O

159/145

306/251

179/106

7.291,0.026

0.550,0.459

0.90

6.637,0.010

1.54

4.781,0.029

1.39

(n = 854)

%b

52.3

54.9

62.8

  

(0.68–1.19)

 

(1.11–2.14)

 

(1.03–1.86)

CKD

stage = 1

(n = 540)

 

134

259

147

52.478,< 0.001

      

%c

44.1

46.5

51.6

       

CKD

stage≥2

(n = 104)

 

25

47

32

7.288,0.026

      

%c

8.2

8.4

11.2

       

CKD

stage≥3

(n = 13)

 

2

4

7

2.923,0.232

      

%c

0.6

0.7

2.5

       
  1. CI confidence interval, OR odds ratio
  2. a The number of the patients of the same genotype with/without the comorbidity (Patients with uncertain status of the comorbidity were excluded)
  3. b The frequency of the comorbidity in the patients with the same genotype (Patients with uncertain status of the comorbidity were excluded)
  4. c The frequency of CKD at a certain stage in the patients with the same genotype (Patients with uncertain status of CKD were excluded)